- Health Canada granted an NOC for Fasenra (benralizumab) as an add-on to standard therapy for patients aged 12+ with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause.
- The approval is supported by the NATRON study, which showed a statistically significant reduction in HES flares and addressed fatigue, a key symptom affecting patients’ quality of life.
- HES comprises rare disorders marked by persistently elevated eosinophils and related organ or tissue damage. If untreated, it can cause progressive organ damage and may be fatal; an estimated 2,000–2,500 Canadians live with HES.
- The approval provides a new treatment option for patients whose HES remains uncontrolled despite current therapies, addressing an unmet need in this rare and potentially serious condition.
Takeaways:
Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentially reducing hospital visits and reliance on high‑dose steroids. For a rare, serious condition affecting an estimated 2,000–2,500 people in Canada, this could shift care toward more consistent disease control and better day‑to‑day functioning, while also encouraging specialists to adopt biologic therapy earlier for eligible patients.
Source: CA Newswire
